China
# |
Name |
Revenue Per Share |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 107.02
|
March 31, 2024 | USD 1.94 | -1.52% |
|
China |
|
2 |
USD 26.96
|
Dec. 31, 2023 | USD 2.59 | 1.33% |
|
China |
|
3 |
USD 19.08
|
Dec. 31, 2023 | USD 3.66 | 2.21% |
|
China |
|
4 |
USD 14.53
|
Dec. 31, 2023 | USD 1.68 | 2.25% |
|
China |
|
5 |
USD 10.07
|
Dec. 31, 2023 | USD 1.40 | 3.01% |
|
China |
|
6 |
USD 9.91
|
Dec. 31, 2023 | USD 1.58 | 1.46% |
|
China |
|
7 |
USD 9.28
|
Dec. 31, 2023 | USD 4.26 | 1.90% |
|
China |
|
8 |
USD 8.31
|
Dec. 31, 2023 | USD 2.85 | 3.99% |
|
China |
|
9 |
USD 8.11
|
Dec. 31, 2023 | USD 2.34 | 2.64% |
|
China |
|
10 |
USD 7.39
|
Dec. 31, 2023 | USD 6.55 | -6.69% |
|
China |
|
11 |
USD 7.23
|
Dec. 31, 2023 | USD 1.10 | 2.94% |
|
China |
|
12 |
USD 6.55
|
Dec. 31, 2023 | USD 0.70 | 2.41% |
|
China |
|
13 |
USD 6.54
|
Dec. 31, 2023 | USD 2.27 | 3.13% |
|
China |
|
14 |
USD 5.84
|
Dec. 31, 2023 | USD 0.65 | 2.15% |
|
China |
|
15 |
USD 5.74
|
Dec. 31, 2023 | USD 1.24 | -0.08% |
|
China |
|
16 |
USD 5.48
|
Dec. 31, 2023 | USD 1.93 | 5.62% |
|
China |
|
17 |
USD 5.41
|
Dec. 31, 2023 | USD 0.67 | 1.67% |
|
China |
|
18 |
USD 5.12
|
Dec. 31, 2023 | USD 12.91 | 2.15% |
|
China |
|
19 |
USD 4.16
|
Dec. 31, 2023 | USD 2.19 | 4.03% |
|
China |
|
20 |
USD 4.08
|
Dec. 31, 2023 | USD 1.67 | 2.01% |
|
China |
|
21 |
USD 4.06
|
Dec. 31, 2023 | USD 32.18 | 1.97% |
|
China |
|
22 |
USD 4.00
|
Dec. 31, 2023 | USD 7.41 | 1.09% |
|
China |
|
23 |
USD 3.96
|
Dec. 31, 2023 | USD 3.00 | 0.74% |
|
China |
|
24 |
USD 3.92
|
Dec. 31, 2023 | USD 4.66 | 4.54% |
|
China |
|
25 |
USD 3.88
|
Dec. 31, 2023 | USD 5.83 | 2.79% |
|
China |
|
26 |
USD 3.66
|
Dec. 31, 2023 | USD 1.47 | 2.19% |
|
China |
|
27 |
USD 3.47
|
Dec. 31, 2023 | USD 5.74 | 2.74% |
|
China |
|
28 |
USD 3.41
|
Dec. 31, 2023 | USD 0.53 | 1.44% |
|
China |
|
29 |
USD 3.25
|
Dec. 31, 2023 | USD 4.53 | 2.64% |
|
China |
|
30 |
USD 3.22
|
Dec. 31, 2023 | USD 4.04 | 10.95% |
|
China |
|
31 |
USD 3.16
|
Dec. 31, 2023 | USD 3.33 | 0.92% |
|
China |
|
32 |
USD 3.11
|
Dec. 31, 2023 | USD 3.45 | 3.36% |
|
China |
|
33 |
USD 3.08
|
Dec. 31, 2023 | USD 7.83 | 2.23% |
|
China |
|
34 |
USD 3.05
|
Dec. 31, 2023 | USD 1.93 | 2.10% |
|
China |
|
35 |
USD 3.05
|
Dec. 31, 2023 | USD 1.46 | 3.48% |
|
China |
|
36 |
USD 3.04
|
Dec. 31, 2023 | USD 10.09 | 5.71% |
|
China |
|
37 |
USD 3.01
|
Dec. 31, 2023 | USD 1.50 | 1.37% |
|
China |
|
38 |
USD 2.93
|
Dec. 31, 2023 | USD 1.37 | 2.36% |
|
China |
|
39 |
USD 2.92
|
Dec. 31, 2023 | USD 1.34 | 1.74% |
|
China |
|
40 |
USD 2.80
|
Dec. 31, 2023 | USD 3.43 | 3.12% |
|
China |
|
41 |
USD 2.76
|
Dec. 31, 2023 | USD 2.49 | 0.18% |
|
China |
|
42 |
USD 2.72
|
Dec. 31, 2023 | USD 5.92 | 1.98% |
|
China |
|
43 |
USD 2.58
|
Dec. 31, 2023 | USD 3.54 | 2.01% |
|
China |
|
44 |
USD 2.52
|
Dec. 31, 2023 | USD 0.99 | 4.49% |
|
China |
|
45 |
USD 2.41
|
Dec. 31, 2023 | USD 48.02 | 4.49% |
|
China |
|
46 |
USD 2.39
|
Dec. 31, 2023 | USD 3.65 | 3.06% |
|
China |
|
47 |
USD 2.37
|
Dec. 31, 2023 | USD 2.19 | 2.04% |
|
China |
|
48 |
USD 2.35
|
Dec. 31, 2023 | USD 28.52 | 2.04% |
|
China |
|
49 |
USD 2.22
|
Dec. 31, 2023 | USD 2.05 | 4.96% |
|
China |
|
50 |
USD 2.17
|
Dec. 31, 2023 | USD 1.71 | 1.65% |
|
China |
The Pharmaceuticals company in China with the highest Revenue Per Share is China Jo-Jo Drugstores, Inc. (NasdaqCM: CJJD) at USD 107.02.
The Pharmaceuticals company in China with the lowest Revenue Per Share is Connect Biopharma Holdings Limited (NasdaqGM: CNTB) at USD 0.00.
The top 10 Pharmaceuticals companies in China by Revenue Per Share are China Jo-Jo Drugstores, Inc., Sinopharm Group Co. Ltd., China National Accord Medicines Corporation Ltd., Cachet Pharmaceutical Co., Ltd., Zhejiang Int'l Group Co.,Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, China National Medicines Corporation Ltd., Yunnan Jianzhijia Health-Chain Co., Ltd., Guangxi LiuYao Group Co., Ltd and Burning Rock Biotech Limited.
The bottom 10 Pharmaceuticals companies in China by Revenue Per Share are Connect Biopharma Holdings Limited, Genor Biopharma Holdings Limited, HighTide Therapeutics Inc, Shanghai Bio-heart Biological Technology Co., Ltd., ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Abbisko Cayman Limited, Zhaoke Ophthalmology Limited, Ascletis Pharma Inc., Jiangsu Recbio Technology Co., Ltd. and Wuhan YZY Biopharma Co Ltd.